PyPy, an alternative runtime for Python, uses a specially created JIT compiler to yield potentially massive speedups over CPython, the conventional Python runtime. But PyPy’s exemplary performance has ...

Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...

Invincible Vs, the fighting game based on Robert Kirkman’s acclaimed comic book series, will launch on April 30, 2026. It will launch with 18 fighters, including an original character made for the ...

It’s happened to all of us: you find the perfect model for your needs — a bracket, a box, a cable clip, but it only comes in STL, and doesn’t quite fit. That problem will never happen if you’re using ...

Ohio State changed the tide of The Game and beat Michigan 27-9 to snap a four-game losing streak in the rivalry. With the return of wide receivers Carnell Tate and Jeremiah Smith from injury, Ohio ...

Python vs. Kotlin: Side-by-side code comparison How does the snake stack up against a new-school JVM language? Prepare to be surprised (video). Hands-on with the new sampling profiler in Python 3.15 ...

Amazon's Ring cancels Flock partnership amid Super Bowl ad backlash 'Rehab Addict' canceled by HGTV after host Nicole Curtis uses racial slur during filming Gun parts manufacturer to pay $1.75m to ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Recursion Pharmaceuticals owns the largest supercomputer in the pharmaceutical industry. However, Eli Lilly is starting to build one that could be even more powerful once it's completed. With its ...

Management reaffirmed guidance for 2025 on an expense base of less than $450 million, "excluding all of the partnership inflows." For 2026, guidance was also reaffirmed at less than $390 million.

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...